Virtual Library
Start Your Search
Ahmet Özet
Author of
-
+
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.16-03 - Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer (ID 13025)
16:45 - 18:00 | Author(s): Ahmet Özet
- Abstract
Background
Prognostic significance of PD-1/PD-L1 axis expression in non-small cell lung cancer (NSCLC) remains uncertain despite being a predictive biomarker for novel immunotherapeutics. In this study, we have investigated PD-1/PD-L1 expression and its effect on disease prognosis and overall survival in stage II-III NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
Clinic and pathologic features of stage II and stage III NSCLC patients were retrospectively analyzed from patients’ records in this study. PD-1 and PD-L1 immunohistochemistry staining were carried out to archived tumor specimens of the eligible patients. Percentages of PD-1 positive lymphocytes, PD-L1 positive tumor cells and PD-L1 positive tumor infiltrating immune cells were evaluated and considered as positive if ≥1% of the cells displayed staining.
4c3880bb027f159e801041b1021e88e8 Result
Sixty-six male (89,2%) and 8 female (10,8%) of total 74 patients were eligible for the study. Thirty-three (44,6%) patients were diagnosed as stage II disease while 41 patients (55,6%) were diagnosed as stage III. PD-1 expression, PD-L1 expression in tumor cells and PD-L1 expression in tumor infiltrating immune cells were positive in 83,8% (n = 62), 45,9% (n = 34), 67,6% (n = 50) of total 74 patients, respectively.Three-year overall survival (OS) rate was calculated as 57,7%. Univariate analyses did not reveal any significant difference in 3-years OS between those with PD-1 and PD-L1 expression in tumor infiltrating immune cells and those without expression. (p = 0,413 and p = 0,099; respectively) However, 3-years OS was more favorable in those with PD-L1 expression in tumor cells than in those without PD-L1 expression (76,6% vs %41%, p = 0.031). In multivariate analyses, a positive trend was revealed in 3-years OS between those with PD-L1 expression in tumor cells and those without expression. (HR: 0,405; 95% CI: 0,153, 1,074; p = 0,069)
8eea62084ca7e541d918e823422bd82e Conclusion
Conclusions: In this study, better prognosis was obtained with positivity of PD-L1 in tumor cells. Therefore, it should be taking into consideration while designing adjuvant immunotherapy trials which are generally formed with stage I-III NSCLC patients, that expression of PD-1/PD-L1 pathway may have a positive prognostic effect.
6f8b794f3246b0c1e1780bb4d4d5dc53